Iterum Therapeutics PLC (NASDAQ:ITRM) Short Interest Update

Iterum Therapeutics PLC (NASDAQ:ITRM) was the target of a significant growth in short interest in February. As of February 27th, there was short interest totaling 2,045,972 shares, a growth of 16.7% from the February 12th total of 1,752,887 shares. Approximately 3.9% of the shares of the stock are sold short. Based on an average trading volume of 839,603 shares, the short-interest ratio is currently 2.4 days. Based on an average trading volume of 839,603 shares, the short-interest ratio is currently 2.4 days. Approximately 3.9% of the shares of the stock are sold short.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Iterum Therapeutics in a research note on Monday, December 22nd. Maxim Group cut Iterum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 4th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $9.00.

Institutional Investors Weigh In On Iterum Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in Iterum Therapeutics in the 2nd quarter worth approximately $92,000. OneDigital Investment Advisors LLC raised its position in Iterum Therapeutics by 18.6% during the third quarter. OneDigital Investment Advisors LLC now owns 191,000 shares of the company’s stock valued at $128,000 after buying an additional 30,000 shares during the period. Virtu Financial LLC purchased a new stake in Iterum Therapeutics in the 3rd quarter worth about $32,000. Apollon Financial LLC lifted its stake in Iterum Therapeutics by 151.8% in the 4th quarter. Apollon Financial LLC now owns 630,250 shares of the company’s stock worth $211,000 after acquiring an additional 380,000 shares in the last quarter. Finally, Alchemi Wealth LLC acquired a new stake in Iterum Therapeutics during the 4th quarter worth about $90,000. Institutional investors and hedge funds own 9.21% of the company’s stock.

Iterum Therapeutics Trading Up 2.2%

NASDAQ:ITRM opened at $0.18 on Thursday. The company has a 50-day moving average of $0.27 and a 200-day moving average of $0.46. The firm has a market cap of $9.34 million, a price-to-earnings ratio of -0.23 and a beta of 2.96. Iterum Therapeutics has a twelve month low of $0.14 and a twelve month high of $1.50.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance.

The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI).